Active	Status	Sponsor type	Region	Phase	Filter
22 Active 0 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

22 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bookman, Ian
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	3	160	Europe, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	08/24	09/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet	Completed	2	153	Europe, Canada, US	TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar	Takeda	Celiac Disease	11/24	11/24
Silverberg, Mark
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease	Recruiting	4	304	Europe, Canada, US, RoW	Vedolizumab	Alimentiv Inc., Takeda	Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn	01/27	09/28
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease	Recruiting	4	150	Canada, US	Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara	Takeda	Crohn's Disease	06/27	06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	Recruiting	4	65	Canada, US	Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550	Takeda	Ulcerative Colitis	07/27	07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
VICTRIVA, NCT06227910: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease	Recruiting	3	396	Canada, US	Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo	Takeda	Crohn's Disease	06/27	08/28
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	207	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Ulcerative Colitis	09/26	08/27
NCT06109441: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics	Active, not recruiting	2	30	Canada, US	ALTB-268	AltruBio Inc.	Ulcerative Colitis	04/25	03/26
NCT04121806: Diet Intervention Treatment for Active Ulcerative Colitis	Recruiting	N/A	20	Canada	UC intervention diet	Mount Sinai Hospital, Canada, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Colitis, Ulcerative	09/23	09/23
NCT05252273: Assessment of Patients With Acute Pouchitis Treated With Antibiotics	Suspended	N/A	43	Europe, Canada, US	Observational, No intervention, Observational	Alimentiv Inc.	Pouchitis, Ulcerative Colitis	02/24	12/24
DIVE-23, NCT06006039: The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.	Recruiting	N/A	40	Europe, Canada		Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Crohn´s Disease	01/26	11/26
NCT06042387: Diverse Ancestry Study in IBD	Recruiting	N/A	150	Canada	Blood or saliva sample collection	Mount Sinai Hospital, Canada, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Ulcerative Colitis, Healthy, Crohn Disease, Inflammatory Bowel Diseases	05/27	09/27
Wang, Qizhi
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis	Recruiting	3	368	Europe, US, RoW	SHR0302, Placebo	Reistone Biopharma Company Limited, Reistone Biopharma Company Limited	Ulcerative Colitis	10/24	03/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT04531475: Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis	Recruiting	2	90	RoW	X842, Undecided, X842 Placebo, Lansoprazole, Lansoprazole Placebo	Jiangsu Sinorda Biomedicine Co., Ltd	Reflux Esophagitis	10/20	12/20